Nyxoah (NASDAQ:NYXH) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Nyxoah (NASDAQ:NYXH) announced its earnings results on Thursday. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04), FiscalAI reports. The company had revenue of $6.62 million during the quarter, compared to analyst estimates of $5.70 million. Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%.

Here are the key takeaways from Nyxoah’s conference call:

• The company received FDA approval for Genio in August 2025, secured Medicare and broad commercial reimbursement, and quickly generated U.S. revenue (about $4.5M in Q4) contributing to EUR 11M global gross revenue and ~EUR 10M net revenue for 2025 with ~63–64% gross margin.
• Commercial execution accelerated: 145 surgeons trained across ~125 targeted accounts, 120 Value Analysis Committee submissions with 57 approvals, and the U.S. sales force expanded from 25 to 40 reps now covering ~200 of the top 400 accounts.
• Clinical and regulatory catalysts are in progress — the DREAM pivotal study was published showing efficacy in supine and non‑supine positions, and 12‑month ACCCESS data are expected by end‑June 2026 to support a PMA supplement and potential U.S. label expansion in early 2027.
• Profitability and cash runway remain challenges: 2025 operating loss widened to EUR 83.5M, cash totaled EUR 48M at year‑end, management estimates ~EUR 20M quarterly cash burn and says current funding supports operations into Q1 2027 absent faster revenue ramp or additional financing.

Nyxoah Stock Up 1.0%

NYXH traded up $0.03 during trading hours on Thursday, hitting $3.09. 19,062 shares of the company’s stock were exchanged, compared to its average volume of 50,584. The stock has a market cap of $105.25 million, a price-to-earnings ratio of -1.24 and a beta of 1.56. Nyxoah has a 1-year low of $3.05 and a 1-year high of $11.87. The stock’s 50-day moving average is $4.41 and its two-hundred day moving average is $4.88. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.40.

Institutional Investors Weigh In On Nyxoah

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. grew its holdings in shares of Nyxoah by 35.6% in the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after acquiring an additional 3,353 shares in the last quarter. Bank of America Corp DE increased its position in shares of Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after acquiring an additional 3,303 shares during the last quarter. Citadel Advisors LLC bought a new stake in Nyxoah during the third quarter worth about $98,000. Deutsche Bank AG raised its holdings in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC acquired a new position in Nyxoah during the second quarter valued at approximately $374,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NYXH. Stifel Nicolaus cut their price target on Nyxoah from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Cantor Fitzgerald upgraded Nyxoah to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nyxoah presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.